EC
SNNA

EcoR1 Capital’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

EcoR1 Capital’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-800,000
Closed -$1.86M – 53
2019
Q1 		$1.86M Buy
+800,000
New +$2.17M 0.17% 40

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

EcoR1 Capital's SNNA Position: Q2 2019 in Review

EcoR1 Capital sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2019, closing a stake of 800,000 shares — an estimated $1.86M sold.

EcoR1 Capital first reported a position in SNNA in Q1 2019 and held it in 1 quarter. The position peaked at $1.86M in Q1 2019. 48 funds tracked by Wall St. Rank hold SNNA as of Q2 2019.

  • EcoR1 Capital reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • EcoR1 Capital sold 800,000 Sienna Biopharmaceuticals, Inc. shares in Q2 2019, an estimated $1.86M.
  • EcoR1 Capital first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • EcoR1 Capital's Sienna Biopharmaceuticals, Inc. position peaked at $1.86M in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2019.

Based on EcoR1 Capital's 13F filing for Q2 2019, filed 14 Aug 2019.